Peter J. Savino

Wills Eye Health System & Wills Eye Institute is a renowned ophthalmology hospital established in 1832 as the first hospital in the United States specializing in eye care. The hospital is located in Philadelphia, PA. Wills Eye is consistently ranked as one of America's top ophthalmology hospitals by U.S. News & World Report and has the most nationally ranked ophthalmologists in the country. It is also the #1 academic training for its residency program as voted by physicians in the nation. Wills Eye provides a full range of primary and subspecialty eye care services, including cataract, cornea, retina, emergency care, glaucoma, neuro-ophthalmology, ocular oncology, oculoplastics, pathology, pediatric ophthalmology and ocular genetics, and refractive surgery. The hospital also has a network of seven multi-specialty, ambulatory surgery centers throughout the tristate area.

The Graduate Hospital operates as a long term rehabilitation facility. The company was founded in 1917 and is headquartered in Philadelphia, PA.

Genaera Corp. develops drugs for asthma, cancer, cystic fibrosis and age-related macular degeneration. It is a biopharmaceutical company committed to developing medicines for serious diseases from genomics and natural products. It's products include EVIZON, to treat ophthalmic indications, specifically age-related macular degeneration. Squalamine lactate, for the treatment of cancerous solid tumors. It's third product candidate, LOMUCIN to treat the overproduction of mucus secretions involved in chronic respiratory disease. Fourth product candidate, interleukin-9 antibody, is a respiratory treatment based on the discovery of a genetic cause of asthma. It also has a number of discovery research programs focused on the treatment of obesity, infectious diseases and inflammatory disorders. The company is headquartered in Plymouth Meeting, PA.